Navigation Links
Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective
Date:5/19/2009 

    NASDAQ: CRME     TSX: COM

VANCOUVER, May 19 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that the waiting period under the Hart-Scott-Rodino Act for the collaboration and license agreement with Merck & Co., Inc. and a Merck affiliate for development and commercialization of vernakalant, an investigational candidate for the treatment of atrial fibrillation, has expired, and the agreement is now effective.

Under terms of the agreement, effectiveness of the agreement triggers an initial payment of US$60 million to Cardiome from Merck. Further terms of the agreement are outlined in our press release dated April 8, 2009.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ National Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Cardiome to Present at Bear Stearns Conference
2. Cardiome to Present at ThinkEquity Conference
3. Cardiome to Present at CIBC Conference
4. Cardiome To Release Third Quarter Results
5. Cardiome Initiates Phase 1 Study for GED-aPC
6. Cardiome Updates Guidance
7. Cardiome to Hold Investor Update Call
8. Cardiome And Astellas Announce Regulatory Update
9. Cardiome Announces Positive Interim Phase 2b Results for Oral Vernakalant and Engages Merrill Lynch as Strategic Advisor
10. Cardiome To Release 2007 Results
11. Cardiome To Release 2008 First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:LCA-Vision's National Lasik Network Named as U.S. Provider for National Vision Administrators 2Health News:LCA-Vision's National Lasik Network Named as U.S. Provider for National Vision Administrators 3Health News:LCA-Vision's National Lasik Network Named as U.S. Provider for National Vision Administrators 4Health News:WuXi AppTec Successfully Holds Its 2009 Supplier Conference in Shanghai 2Health News:WuXi AppTec Successfully Holds Its 2009 Supplier Conference in Shanghai 3Health News:New Occupational Therapy School and Career Resource on All Allied Health Schools 2Health News:New Occupational Therapy School and Career Resource on All Allied Health Schools 3Health News:Compass Pharma Services Offers Microfill Capabilities to Contract Pharmaceutical Packaging Customers 2Health News:Helping to Clear the Air for Consumers - New Certification Standard for HEPA Filters Will Help Millions of People Make More Educated Choices 2Health News:Official Launch of ABLE TO CHOOSE Public Awareness Campaign 2
Breaking Medicine Technology:Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 2AdvanDx Receives FDA 510(k) Clearance for 90 Minutes PNA FISH(R) Protocol for Identifying Staphylococcal Bloodstream Pathogens 3Free Spanish Language Online Video Teaches Hands Only 28TM 29 CPR 57120 1Free Spanish Language Online Video Teaches Hands Only 28TM 29 CPR 57120 2Amgen to Present at the Bank of America Merrill Lynch Global Healthcare Conference 14034 1Small Businesses Urged to Prepare for Swine Flu 57118 1Small Businesses Urged to Prepare for Swine Flu 57118 2